Bilateral neck of femur fracture induced by osteomalacia secondary to phosphaturic mesenchymal tumor of paranasal sinus: a case report
DOI:
https://doi.org/10.18203/issn.2455-4510.IntJResOrthop20251823Keywords:
Phosphaturic mesenchymal tumor, Tumor-induced osteomalacia, Hypophosphatemia, Fragility fractures, FGF23, Femoral neck fracture, Metabolic bone diseaseAbstract
Phosphaturic mesenchymal tumors (PMTs) are rare, often occult neoplasms that cause tumor-induced osteomalacia (TIO) due to excessive fibroblast growth factor 23 (FGF23) secretion, leading to phosphate wasting, hypophosphatemia, and impaired bone mineralization. This results in progressive skeletal fragility and increased fracture risk. We present a 53-year-old male with bilateral femoral neck fractures following a trivial fall, accompanied by generalized myalgia. MRI of the hip and pelvis revealed bilateral femoral neck fractures with sclerotic changes in the superior and inferior pubic rami, sacral ala, and bilateral iliac wings. Laboratory investigations confirmed severe hypophosphatemia and osteomalacia. Further imaging and biopsy identified a phosphaturic mesenchymal tumor in the right anterior ethmoidal sinus as the underlying cause. The patient underwent bilateral femoral neck fracture fixation with cannulated cancellous (CC) screws, along with vitamin D and phosphate supplementation. The PMT was surgically resected to correct the metabolic disorder. Postoperatively, the patient demonstrated significant clinical and biochemical improvement. This case highlights the critical need to consider PMT in patients presenting with unexplained fractures and persistent hypophosphatemia. Early detection, surgical resection of the tumor, and appropriate metabolic correction are essential for optimal recovery and fracture healing.
Metrics
References
Carpenter TO. Primary disorders of phosphate metabolism. Endotext. 2022. Available at: https://www.ncbi.nlm.nih.gov. Accessed on 18 December 2024.
Chong WH, Molinolo AA, Chen CC, Collins MT. Tumor-induced osteomalacia. Endocr Relat Cancer. 2011;18(3):53-77. DOI: https://doi.org/10.1530/ERC-11-0006
Shane E, Parisien M, Henderson JE, Dempster DW, Feldman F, Hardy MA, et al. Tumor-induced osteomalacia: clinical and basic studies. J Bone Miner Res. 1997;12(9):1502-11. DOI: https://doi.org/10.1359/jbmr.1997.12.9.1502
Siris ES, Clemens TL, Dempster DW, Shane E, Segre GV, Lindsay R, et al. Tumor-induced osteomalacia. Kinetics of calcium, phosphorus, and vitamin D metabolism and characteristics of bone histomorphometry. Am J Med. 1987;82(2):307-12. DOI: https://doi.org/10.1016/0002-9343(87)90075-1
Geller JL, Khosravi A, Kelly MH, Riminucci M, Adams JS, Collins MT. Cinacalcet in the management of tumor-induced osteomalacia. J Bone Miner Res. 2007;22(6):931-7. DOI: https://doi.org/10.1359/jbmr.070304
Jiang Y, Xia WB, Xing XP, Silva BC, Li M, Wang O, et al. Tumor-induced osteomalacia: an important cause of adult-onset hypophosphatemic osteomalacia in China: Report of 39 cases and review of the literature. J Bone Miner Res. 2012;27(9):1967-75. DOI: https://doi.org/10.1002/jbmr.1642
Folpe AL. Phosphaturic mesenchymal tumors: A review and update. Semin Diagn Pathol. 2019;36(4):260-8. DOI: https://doi.org/10.1053/j.semdp.2019.07.002
Fukumoto S. FGF23-related hypophosphatemic rickets/osteomalacia: diagnosis and new treatment. J Mol Endocrinol. 2021;66(2):57-65. DOI: https://doi.org/10.1530/JME-20-0089
Razzaque MS. The FGF23-Klotho axis: endocrine regulation of phosphate homeostasis. Nat Rev Endocrinol. 2009;5(11):611-9. DOI: https://doi.org/10.1038/nrendo.2009.196
Lee JC, Su SY, Changou CA, Yang RS, Tsai KS, Collins MT, et al. Characterization of FN1-FGFR1 and novel FN1-FGF1 fusion genes in a large series of phosphaturic mesenchymal tumors. Mod Pathol. 2016;29(11):1335-46. DOI: https://doi.org/10.1038/modpathol.2016.137
Garg B, Mehta N, Goyal A, Khadgawat R. Oncogenic osteomalacia due to phosphaturic mesenchymal tumour in the upper thoracic spine. BMJ Case Reports CP. 2020;13(12):238209. DOI: https://doi.org/10.1136/bcr-2020-238209
Feng J, Jiang Y, Wang O, Li M, Xing X, Huo L, et al. The diagnostic dilemma of tumor induced osteomalacia: a retrospective analysis of 144 cases. Endocr J. 2017;64(7):675-83. DOI: https://doi.org/10.1507/endocrj.EJ16-0587
Brandi ML, Clunie GPR, Houillier P, Jan de Beur SM, Minisola S, Oheim R, et al. Challenges in the management of tumor-induced osteomalacia (TIO). Bone. 2021;152:116064. DOI: https://doi.org/10.1016/j.bone.2021.116064
Folpe AL, Fanburg-Smith JC, Billings SD, Bisceglia M, Bertoni F, Cho JY, et al. Most osteomalacia-associated mesenchymal tumors are a single histopathologic entity: an analysis of 32 cases and a comprehensive review of the literature. Am J Surg Pathol. 2004;28(1):1-30. DOI: https://doi.org/10.1097/00000478-200401000-00001
Zhang Y, Hu M, Guo C, Yang X, Xiang S, Xu H. Phosphaturic mesenchymal tumor-induced bilateral osteomalacia femoral neck fractures: a case report. Front Endocrinol (Lausanne). 2024;15:1373794. DOI: https://doi.org/10.3389/fendo.2024.1373794